# Adaptin Bio

Source: https://onco.cc/companies/adaptin-bio/  
OnCo record `adaptin-bio` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Adaptin Bio is a North Carolina company working on ways to get immune treatments past the barrier that protects the brain. Its first medicine, APTN-101, is in an early trial at Duke University in glioblastoma.

## Summary

Adaptin Bio, Inc., of Charlotte, North Carolina, develops technology originally from the Department of Neurosurgery at Duke University, led by John H. Sampson, that uses activated T cells to carry bound molecules across the blood-brain barrier. Its first platform, BRiTE (Brain Bispecific T-cell Engager), pairs this with a tumour-specific, fully human bispecific antibody. The first product, APTN-101, is an EGFRvIII x CD3 BRiTE. The FDA accepted an investigator-initiated IND in May 2023 and a multi-dose amendment in October 2025, and in August 2026 Duke opened an investigator-initiated phase 1 trial of hEGFRvIII-CD3 bi-scFv in WHO grade 4 malignant glioma.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Adaptin Bio, Inc.
- HQ: Charlotte, NC
- Type: biotech
- Website: https://www.adaptinbio.com/
- Ticker: APTN

## Notes

- Read on 4 November 2026 in the S-1 filed with the SEC on 28 August 2026. The trial registry number is not given in the filing.

## Sources

- SEC: Adaptin Bio Form S-1, August 2026: https://www.sec.gov/Archives/edgar/data/1938571/000121390026095034/ea0303043-s1_adaptin.htm
- Official website: https://www.adaptinbio.com/

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/)
- drugs: [APTN-101](https://onco.cc/drugs/aptn-101/)

---
JSON: https://onco.cc/api/v1/entities/adaptin-bio.json